{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Radium+ra+223+dichloride",
    "query": {
      "intervention": "Radium ra 223 dichloride"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 55,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Radium+ra+223+dichloride&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-24T07:53:15.137Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02023697",
      "title": "Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "Radium-223 dichloride (Xofigo, BAY88-8223)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 391,
      "start_date": "2014-03-10",
      "completion_date": "2018-08-09",
      "has_results": true,
      "last_update_posted_date": "2019-07-12",
      "last_synced_at": "2026-09-24T07:53:15.137Z",
      "location_count": 12,
      "location_summary": "Scottsdale, Arizona • New Haven, Connecticut • Fort Myers, Florida + 9 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Rockville",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02023697"
    },
    {
      "nct_id": "NCT02429804",
      "title": "NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hormone-Resistant Prostate Cancer",
        "Metastatic Malignant Neoplasm in the Bone",
        "Metastatic Prostate Carcinoma"
      ],
      "interventions": [
        {
          "name": "Contrast-enhanced Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Fludeoxyglucose F-18",
          "type": "DRUG"
        },
        {
          "name": "Fluorine F 18 Sodium Fluoride",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "19 Years and older · Male only"
      },
      "enrollment_count": 4,
      "start_date": "2015-04",
      "completion_date": "2017-05-15",
      "has_results": false,
      "last_update_posted_date": "2017-05-30",
      "last_synced_at": "2026-09-24T07:53:15.137Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02429804"
    },
    {
      "nct_id": "NCT01934790",
      "title": "Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Prostatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "Radium-223 dichloride (Xofigo, BAY88-8223)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 45,
      "start_date": "2013-12-22",
      "completion_date": "2017-04-12",
      "has_results": true,
      "last_update_posted_date": "2018-03-26",
      "last_synced_at": "2026-09-24T07:53:15.137Z",
      "location_count": 3,
      "location_summary": "New Orleans, Louisiana • Omaha, Nebraska • Syracuse, New York",
      "locations": [
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Syracuse",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01934790"
    },
    {
      "nct_id": "NCT02097303",
      "title": "Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Concurrent use of Radium Ra 223 dichloride and Abiraterone Acetate plus Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Carolina Research Professionals, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 36,
      "start_date": "2014-03",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2018-02-01",
      "last_synced_at": "2026-09-24T07:53:15.137Z",
      "location_count": 5,
      "location_summary": "Towson, Maryland • Omaha, Nebraska • Syracuse, New York + 2 more",
      "locations": [
        {
          "city": "Towson",
          "state": "Maryland"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Syracuse",
          "state": "New York"
        },
        {
          "city": "Springfield",
          "state": "Oregon"
        },
        {
          "city": "Myrtle Beach",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02097303"
    },
    {
      "nct_id": "NCT02507570",
      "title": "Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Carcinoma Metastatic to the Bone"
      ],
      "interventions": [
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Radium ra 223 dichloride",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Carolina Research Professionals, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 40,
      "start_date": "2015-09-23",
      "completion_date": "2019-01-18",
      "has_results": false,
      "last_update_posted_date": "2019-03-19",
      "last_synced_at": "2026-09-24T07:53:15.137Z",
      "location_count": 4,
      "location_summary": "Towson, Maryland • Syracuse, New York • Myrtle Beach, South Carolina + 1 more",
      "locations": [
        {
          "city": "Towson",
          "state": "Maryland"
        },
        {
          "city": "Syracuse",
          "state": "New York"
        },
        {
          "city": "Myrtle Beach",
          "state": "South Carolina"
        },
        {
          "city": "Virginia Beach",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02507570"
    },
    {
      "nct_id": "NCT03996473",
      "title": "Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "Radium-223 dichloride (Xofigo, BAY 88-8223)",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2020-03-06",
      "completion_date": "2023-01-30",
      "has_results": true,
      "last_update_posted_date": "2024-10-10",
      "last_synced_at": "2026-09-24T07:53:15.137Z",
      "location_count": 1,
      "location_summary": "San Marcos, California",
      "locations": [
        {
          "city": "San Marcos",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03996473"
    },
    {
      "nct_id": "NCT03414437",
      "title": "Post-eRADicAte - A Long Term Follow up of Subjects That Completed the eRADicAte Study (NCT 02097303)",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Prostate Cancer Metastatic"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Carolina Research Professionals, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 31,
      "start_date": "2017-10-01",
      "completion_date": "2021-10-01",
      "has_results": false,
      "last_update_posted_date": "2019-03-19",
      "last_synced_at": "2026-09-24T07:53:15.137Z",
      "location_count": 5,
      "location_summary": "Towson, Maryland • Omaha, Nebraska • Syracuse, New York + 2 more",
      "locations": [
        {
          "city": "Towson",
          "state": "Maryland"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Syracuse",
          "state": "New York"
        },
        {
          "city": "Springfield",
          "state": "Oregon"
        },
        {
          "city": "Myrtle Beach",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03414437"
    },
    {
      "nct_id": "NCT03361735",
      "title": "Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Leuprolide Acetate",
          "type": "DRUG"
        },
        {
          "name": "Goserelin Acetate",
          "type": "DRUG"
        },
        {
          "name": "Stereotactic Body Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Radium Ra 223 Dichloride",
          "type": "RADIATION"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Degarelix",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2018-08-29",
      "completion_date": "2027-01-06",
      "has_results": true,
      "last_update_posted_date": "2026-04-09",
      "last_synced_at": "2026-09-24T07:53:15.137Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03361735"
    },
    {
      "nct_id": "NCT02258464",
      "title": "Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "Radium-223 dichloride (Xofigo, BAY88-8223)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (saline)",
          "type": "DRUG"
        },
        {
          "name": "Background hormonal therapy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 99,
      "start_date": "2015-03-02",
      "completion_date": "2019-08-13",
      "has_results": true,
      "last_update_posted_date": "2020-08-10",
      "last_synced_at": "2026-09-24T07:53:15.137Z",
      "location_count": 11,
      "location_summary": "Bakersfield, California • La Jolla, California • Aurora, Colorado + 8 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Cedar Rapids",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02258464"
    },
    {
      "nct_id": "NCT03737370",
      "title": "Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Castrate Resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Radium 223",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Tufts Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2018-01-30",
      "completion_date": "2025-09-30",
      "has_results": false,
      "last_update_posted_date": "2025-10-07",
      "last_synced_at": "2026-09-24T07:53:15.137Z",
      "location_count": 4,
      "location_summary": "Boston, Massachusetts • Detroit, Michigan • Columbus, Ohio",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03737370"
    }
  ]
}